Zentek (ZTEK)

The company’s strategy centres on creating, protecting, and licensing or commercializing proprietary technologies rather than operating as a conventional manufacturer. Its near-term opportunity is tied to products that may benefit from antimicrobial or enhanced filtration properties, including personal protective equipment and air-quality applications. Zentek also explores related compounds and platforms that could have uses in prevention, detection, or treatment of infectious disease, positioning the business at the intersection of nanotechnology, biotechnology, and applied healthcare innovation.

For investors, Zentek represents an early-stage commercialization story. Its value depends on regulatory progress, customer adoption, manufacturing partnerships, and the ability to convert intellectual property into recurring revenue. The company’s technologies address markets that became more prominent after the COVID-19 pandemic, particularly infection prevention and indoor air quality. However, as with many IP-led businesses, execution risk is significant and commercialization timelines can be uneven. Zentek’s appeal lies in the potential for differentiated materials technology to solve practical health and safety problems across multiple end markets.